Skip to content
10-Q

Quarterly Report

BioXcel Therapeutics, Inc. BTAI

0001104659-26-061769

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 14, 2026 30.88M sh
Shares Diluted Q1 2026 · Mar 31, 2026 23.57M sh
Shares Diluted Q1 2026 · Mar 31, 2025 4.83M sh
Capex Q1 2026 · Mar 31, 2026 $0
Capex Q1 2026 · Mar 31, 2025 $0
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$11.81M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$12.04M
Long Term Debt Q1 2026 · Mar 31, 2026 $77.86M
Long Term Debt Q1 2026 · Dec 31, 2025 $84.66M
Short Term Debt Q1 2026 · Mar 31, 2026 $22.43M
Short Term Debt Q1 2026 · Dec 31, 2025 $24.93M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $17.18M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $28.42M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$105.54M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$95.46M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$90.17M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$93.1M
Current Liabilities Q1 2026 · Mar 31, 2026 $54.99M
Current Liabilities Q1 2026 · Dec 31, 2025 $53.93M
Total Liabilities Q1 2026 · Mar 31, 2026 $139.57M
Total Liabilities Q1 2026 · Dec 31, 2025 $140.38M
Current Assets Q1 2026 · Mar 31, 2026 $33.91M
Current Assets Q1 2026 · Dec 31, 2025 $44.69M
Total Assets Q1 2026 · Mar 31, 2026 $34.03M
Total Assets Q1 2026 · Dec 31, 2025 $44.92M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.54
Eps Diluted Q1 2026 · Mar 31, 2025 −$1.50
Eps Basic Q1 2026 · Mar 31, 2026 −$0.54
Eps Basic Q1 2026 · Mar 31, 2025 −$1.50
Sga Expense Q1 2026 · Mar 31, 2026 $7.19M
Sga Expense Q1 2026 · Mar 31, 2025 $5.7M
Rd Expense Q1 2026 · Mar 31, 2026 $2.96M
Rd Expense Q1 2026 · Mar 31, 2025 $4.55M
Net Income Q1 2026 · Mar 31, 2026 −$12.69M
Net Income Q1 2026 · Mar 31, 2025 −$7.25M
Operating Income Q1 2026 · Mar 31, 2026 −$10.22M
Operating Income Q1 2026 · Mar 31, 2025 −$10.1M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $283K
Cost Of Revenue Q1 2026 · Mar 31, 2025 $14K
Revenue Q1 2026 · Mar 31, 2026 $206K
Revenue Q1 2026 · Mar 31, 2025 $168K